# Viking starts Part 2 of VK2735 oral maintenance-dosing study in about 195 adults with obesity

Canonical page: https://technooptimist.io/stories/viking-starts-part-2-of-vk2735-oral-maintenance-dosing-study-in-about-99e65925
Date: 6 Oct 2026
About: [Viking Therapeutics](https://technooptimist.io/companies/viking-therapeutics.md) · [VK2735](https://technooptimist.io/biotech/vk2735.md)
Original source: https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity

Viking Therapeutics announced on October 6, 2026 the start of Part 2 of an exploratory study testing maintenance regimens for its GLP-1/GIP drug VK2735. Part 2 compares daily and weekly oral doses, monthly and every-other-week injections, and placebo after 21 weeks of weekly injections. The company expects to report Part 2 results in 2027. This is a separate study from the oral VANQUISH Phase 3 trial, which the announcement does not mention.

## Key facts

- About 195 adults with obesity (BMI 30 or higher), randomized, double-blind and placebo-controlled.
- All participants first receive weekly subcutaneous VK2735 or placebo for 21 weeks, then move to a maintenance option.
- Part 1 of the same study, which tested subcutaneous maintenance regimens, has already reported positive top-line results.
- Results from Part 2 are expected in 2027.
- The announcement does not confirm a start date for the oral VANQUISH Phase 3 trial, which the company guided to Q4 2026.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.